Personalized Cancer Treatment for Ovarian Cancer

Recently there have been numerous advances in understanding the genetic basis of cancer which have resultedin more appropriate treatments. In this paper we describe the experience of the Burzynski Clinic, involved intreatment of numerous patients based on personalized approach using novel combinations for difficult-to-treatmalignancies, with gynecological cancers. This retrospective study was conducted by extracting data fromBurzynski Clinic’s medical records and comprehensive review. Among the advanced refractory ovarian cancerscases (N=33), an objective response (OR) was found in 42.4%. We anticipate that with improved technology andnovel therapeutics this rate will increase and adverse events will be reduced.     

肿瘤干细胞与肿瘤转移

肿瘤干细胞和其微环境住肿瘤形成、浸润性生长和转移灶形成等各步骤均具有关键性作用。阐明其相互作用的分子机制，可为肿瘤转移的诊断、治疗和预后，提供可靠的分子标志和靶点：文章主要就以上进行综述。     

Esophageal Cancer Associated with Gastric Cancer

Among a total of 1,137 patients with esophageal cancer, therewere 44 cases of esophageal cancer associated with gastric cancer,an incidence of 3.9%. The majority of the patients were between60 and 70 yr old. Forty-two patients were male and two werefemale. Eleven of these patients had a third cancer. Six had multiplecancers in the esophagus and/or stomach. Eighteen patients hadearly gastric cancer. Thirty-two of the cancers were synchronousand 12 were metachronous. Of these 44 patients, 21 had familyhistories of cancer, 37 were smokers, and 36 were drinkers.Twenty-five patients received surgery for all of their cancers,and two patients received resection of only esophageal cancer.Of these 27 patients. five patients lived more than 5 yr. Themost frequent cause of death in our series was esophageal cancer(52.9%). Surgical treatment of all of the cancers is desirable. Whenthis is impossible, the surgery must be emphasized for the esophagealcancer in most cases.     

National Cancer Institute Prostate Cancer Genetics Workshop

Compelling evidence supports a genetic component to prostate cancer susceptibility and aggressiveness. Recent genome-wide association studies have identified more than 30 single-nucleotide polymorphisms associated with prostate cancer susceptibility. It remains unclear, however, whether such genetic variants are associated with disease aggressiveness--one of the most important questions in prostate cancer research today. To help clarify this and substantially expand research in the genetic determinants of prostate cancer aggressiveness, the first National Cancer Institute Prostate Cancer Genetics Workshop assembled researchers to develop plans for a large new research consortium and patient cohort. The workshop reviewed the prior work in this area and addressed the practical issues in planning future studies. With new DNA sequencing technology, the potential application of sequencing information to patient care is emerging. The workshop, therefore, included state-of-the-art presentations by experts on new genotyping technologies, including sequencing and associated bioinformatics issues, which are just beginning to be applied to cancer genetics.     

Europe Against Cancer: Cancer Week UK

Since the beginning of the Europe Against Cancer (EAC) programme in 1989, much support and emphasis has been given to informing both health professionals and the public about cancer. This has come from the government and the many cancer-related charities and organizations. A week focused on cancer throughout the European Union (EU) has been encouraged each October. This paper describes the gradual development of these weeks to provide a more planned, co-ordinated and evaluated strategy. Collaboration with European partners is also addressed, emphasizing the positive benefits of such activities. Finally, the issue of monitoring and evaluation is addressed in some detail.     

干细胞、癌症与癌症干细胞

干细胞被认为是一种未分化的细胞,具有永远增殖和自我更新能力.大量研究证明,癌症中存在对化疗更具抵抗性的癌症干细胞.识别癌症干细胞和普通癌症细胞之间的差异,可以发展更有效的癌症分类、诊断和治疗方法.     

American Cancer Society Colorectal Cancer Survivorship Care Guidelines

Answer questions and earn CME/CNE Colorectal cancer (CRC) is the third most common cancer and third leading cause of cancer death in both men and women and second leading cause of cancer death when men and women are combined in the United States (US). Almost two‐thirds of CRC survivors are living 5 years after diagnosis. Considering the recent decline in both incidence and mortality, the prevalence of CRC survivors is likely to increase dramatically over the coming decades with the increase in rates of CRC screening, further advances in early detection and treatment and the aging and growth of the US population. Survivors are at risk for a CRC recurrence, a new primary CRC, other cancers, as well as both short‐term and long‐term adverse effects of the CRC and the modalities used to treat it. CRC survivors may also have psychological, reproductive, genetic, social, and employment concerns after treatment. Communication and coordination of care between the treating oncologist and the primary care clinician is critical to effectively and efficiently manage the long‐term care of CRC survivors. The guidelines in this article are intended to assist primary care clinicians in delivering risk‐based health care for CRC survivors who have completed active therapy. CA Cancer J Clin 2015;65:427–455 . © 2015 American Cancer Society.